CAS 204067-01-6: 3-(1H-Indol-3-yl)-N-[1-(5-methoxy-2-pyridinyl)cyclohexylmethyl]-2(S)-methyl-2-[3-(4-nitrophenyl)ureido]propionamide

PD 176252 is a cytosolic calcium ionophore that has been shown to enhance the cytotoxicity of cisplatin in cancer cells. It binds to cyclic adenosine monophosphate (cAMP) and increases intracellular calcium concentrations by opening the channels of R-type voltage dependent calcium channels. PD 176252 also inhibits epidermal growth factor receptor tyrosine kinase activity, which may contribute its anti-cancer effects. The molecular modeling study showed that PD 176252 binds to the peptide binding site on metalloproteases by hydrogen bonding with the backbone amide group of Asp residues, which are often found in this region. This drug does not inhibit proteolysis, but blocks the catalytic domain of metalloproteases from binding to substrates.

PD176252 is a BB1 and BB2 antagonist, GRPR inhibitor, and FPR1/FPR2 agonist that inhibits the growth and proliferation of a wide range of cancer cells.